Team:Berkeley/Human Practices

From 2010.igem.org

(Difference between revisions)
(Human Practices: Rethinking Biosafety)
(Human Practices: Rethinking Biosafety)
Line 5: Line 5:
<!-- Insert actual content below -->
<!-- Insert actual content below -->
-
=Human Practices: Rethinking Biosafety=
+
<font size="8">'''Human Practices: Rethinking Biosafety'''</font>
-
==Current Biosafety Standards==
+
<font size="5"> '''Current Biosafety Standards'''</font>
Biosafety is undoubtedly one of the highest priorities of any synthetic biology institution. When manipulating systems as complex as the cell, there is always high degree of uncertainty. Unexpected results in living constructs have the potential to be disastrous, especially when dealing with pathogenic organisms or virulence factors. The NIH and CDC have developed a standard of biosafety levels (BSL) to rate the risk factor associated with different biological agents and genetic parts. They are summarized here:
Biosafety is undoubtedly one of the highest priorities of any synthetic biology institution. When manipulating systems as complex as the cell, there is always high degree of uncertainty. Unexpected results in living constructs have the potential to be disastrous, especially when dealing with pathogenic organisms or virulence factors. The NIH and CDC have developed a standard of biosafety levels (BSL) to rate the risk factor associated with different biological agents and genetic parts. They are summarized here:
*''BSL 1''- Well characterized parts and organisms that are not consistently pathogenic to healthy adults.
*''BSL 1''- Well characterized parts and organisms that are not consistently pathogenic to healthy adults.
Line 16: Line 16:
The current system of rating synthetic biological devices simply chooses the highest rated part or gene within the device and rates the entire device based on that number. For example, we could not submit our Vesicle Lysis parts this year because they contained genes from the pathogen "Clostridium perfringens", making the entire device BSL2.  
The current system of rating synthetic biological devices simply chooses the highest rated part or gene within the device and rates the entire device based on that number. For example, we could not submit our Vesicle Lysis parts this year because they contained genes from the pathogen "Clostridium perfringens", making the entire device BSL2.  
-
==Shortcomings of the System==
+
<font size="5"> '''Shortcomings of the Systemt''</font>
-
The CDC is wary of recombinant
+
As synthetic biology becomes more sophisticated, and genes from various organisms are mixed to create novel tools,
 +
the threat of creating dangerous constructs from innocent parts becomes real. We encountered this very danger in our product. We created an engineered organism that used a Self Lysis device (made up of ''BSL''1 parts) to release its contents inside vesicles and a Vesicle Buster device (which contains ''BSL''2 parts)to break out of any cholesterol-based vesicle membrane. This device has been shown to function in mammalian cells. Lastly, we constructed a number of transposase devices (all ''BSL''1) to potentially integrate transposons into our target's DNA. The combination of these three devices

Revision as of 06:22, 26 October 2010



Human Practices: Rethinking Biosafety

Current Biosafety Standards Biosafety is undoubtedly one of the highest priorities of any synthetic biology institution. When manipulating systems as complex as the cell, there is always high degree of uncertainty. Unexpected results in living constructs have the potential to be disastrous, especially when dealing with pathogenic organisms or virulence factors. The NIH and CDC have developed a standard of biosafety levels (BSL) to rate the risk factor associated with different biological agents and genetic parts. They are summarized here:

  • BSL 1- Well characterized parts and organisms that are not consistently pathogenic to healthy adults.
  • BSL 2- Associated with mild human diseases, but do not readily spread through aerosols
  • BSL 3- Associated with deadly or severe human diseases that we have vaccines or treatments for.
  • BSL 4- Associated with deadly, aerosol-spread diseases that have no known vaccine or treatment

The current system of rating synthetic biological devices simply chooses the highest rated part or gene within the device and rates the entire device based on that number. For example, we could not submit our Vesicle Lysis parts this year because they contained genes from the pathogen "Clostridium perfringens", making the entire device BSL2.

'Shortcomings of the Systemt As synthetic biology becomes more sophisticated, and genes from various organisms are mixed to create novel tools, the threat of creating dangerous constructs from innocent parts becomes real. We encountered this very danger in our product. We created an engineered organism that used a Self Lysis device (made up of BSL1 parts) to release its contents inside vesicles and a Vesicle Buster device (which contains BSL2 parts)to break out of any cholesterol-based vesicle membrane. This device has been shown to function in mammalian cells. Lastly, we constructed a number of transposase devices (all BSL1) to potentially integrate transposons into our target's DNA. The combination of these three devices